Company: EDSA
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001171843-25-000866
Chunk: 9

Company: Edesa Biotech, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 8
Chunk 9
---
31, 2024

			936,277

			$
			15.36

			Three Months Ended December 31, 2023

			Balance - September 30, 2023

			720,909

			$
			19.51

			Expired

			(110,122
			)

			7.00

			Balance - December 31, 2023

			610,787

			$
			21.76

The weighted average contractual life remaining on the outstanding warrants at December 31, 2024 is 37 months.

The following table summarizes information about the warrants outstanding at December 31, 2024:

			Number of Warrants (#)

			Exercise Prices 

			Expiry Dates

			1,687
			 
			$
			22.40

			January 2025

			173,614
			 
			$
			10.50

			December 2025

			15,627
			 
			$
			56.00

			February 2026

			27,399
			 
			$
			31.94

			March 2027

			391,390
			 
			$
			24.64

			September 2027

			326,560
			 
			$
			3.45

			October 2029

			936,277

The fair value of warrants granted during the three months ended December 31, 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Three Months Ended

			December 31, 2024

			Class A Pref Share

			Risk free interest rate

			4.14
			%

			Expected life

			5 years

			Expected share price volatility

			91.24
			%

			Expected dividend yield

			0.00
			%

Share options

The Company adopted an Equity Incentive Compensation Plan in 2019 (the 2019 Plan) administered by the independent members of the board of directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan